Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

Fig. 1

Duration of remission, relapse-free survival, and overall survival for all phase 2 treated patients (N = 55). Kaplan–Meier estimates of the duration of remission by central assessment, with (A) and without (B) censoring of patients at subsequent allogeneic stem cell transplant. C Kaplan–Meier estimate of relapse-free survival by central assessment, with censoring of patients at subsequent allogeneic stem cell transplant. D Kaplan–Meier estimate of overall survival. CR = complete remission. CRi = complete remission with incomplete hematological recovery. Mo = month. NE = not estimable

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us